2009.08.05 – Onyx Pharmaceuticals – ONX 0803 selective JAK2 inhibitor
Seeking Alpha – New York,NY,USA
Onyx Pharmaceuticals – ONX 0803 selective JAK2 inhibitor
Clinical development of ONX 0803 selective JAK2 inhibitor is ongoing and we expect Phase I results this year. As you recall, we have an option to acquire …
Beyond Nexavar, we have begun building a pipeline with compelling compounds by focusing on identifying and acquiring next generation therapies with broad potential utility. Clinical development of ONX 0803 selective JAK2 inhibitor is ongoing and we expect Phase I results this year. As you recall, we have an option to acquire the development and commercialization rights to all potential indications in the US and Europe for this compound, and for ONX 0805.
Depending upon the results of the Phase I studies for 0803, we may be in a position to exercise our option in this agent before year end. In addition, we are planning to initiate a Phase I trial for ONX 0801, the first in class targeted alpha-folate receptor inhibitor by the end of the year. As we move forward, we continue to evaluate a wide range of corporate development opportunities. We are excited to have already accomplished many of the goals we set out to achieve this year. We believe Nexavar is on the path to block bluster status and that our expanding pipeline compelling clinical programs and ongoing corporate development efforts position Onyx to continue to grow and build sustainable value.